Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus
Condition(s):Systemic Lupus ErythematosusLast Updated:April 28, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Systemic Lupus ErythematosusLast Updated:April 28, 2022Recruiting
Condition(s):Systemic Lupus ErythematosusLast Updated:June 12, 2023Recruiting
Condition(s):Systemic Lupus ErythematosusLast Updated:March 15, 2023Recruiting
Condition(s):Systemic Lupus ErythematosusLast Updated:October 7, 2016Completed
Condition(s):Systemic Lupus ErythematosusLast Updated:February 26, 2020Completed
Condition(s):Systemic Lupus ErythematosusLast Updated:February 28, 2024Recruiting
Condition(s):Systemic Lupus ErythematosusLast Updated:July 12, 2018Unknown status
Condition(s):Systemic Lupus ErythematosusLast Updated:December 20, 2022Completed
Condition(s):Metabolic Syndrome; Cardiovascular Risk Factors; Systemic Lupus ErythematosusLast Updated:September 23, 2009Completed
Condition(s):Systemic Lupus ErythematosusLast Updated:March 27, 2024Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.